NCT06971406View on ClinicalTrials.gov

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

June 1, 2027

Conditions

Non Small Cell Lung CancerEGFR MutationLeptomeningeal MetastasesTargeted Therapy

Interventions

DRUG

Combination therapy prospective cohort

high-dose firmonertinib (240 mg, daily), bevacizumab (15 mg/kg, every 3 weeks), and pemetrexed (50 mg, intrathecal chemotherapy C1d1d5, then every 3 weeks)

All Listed Sponsors

lead

Qiming Wang

OTHER_GOV